³Department of Neuropediatrics, Tokyo Metropolitan Neurological Hospital, Fuchu, Tokyo, Japan

⁴Department of Neuroradiology, Tokyo Metropolitan Neurological Hospital, Fuchu, Tokyo, Japan

⁵Department of Biochemistry, Hamamatsu University School of Medicine, Shizuoka, Japan

References

- 1. Kleiner-Fisman G. Benign hereditary chorea. Handb Clin Neurol 2011;100:199-212.
- Thorwarth A, Schnittert-Hubener S, Schrumpf P, et al. Comprehensive genotyping and clinical characterisation reveal 27 novel NKX2-1 mutations and expand the phenotypic spectrum. J Med Genet 2014;51(6):375-387.
- 3. Carecchio M, Mencacci NE, Iodice A, et al. ADCY5-related movement disorders: frequency, disease course and phenotypic variability in a cohort of paediatric patients. Parkinsonism Relat Disord 2017;41:37-43.
- Mencacci NE, Kamsteeg EJ, Nakashima K, et al. De novo mutations in PDE10A cause childhood-onset chorea with bilateral striatal lesions. Am J Hum Genet 2016;98:763-771.
- Mizuguchi T, Nakashima M, Kato M, et al. PARS2 and NARS2 mutations in infantile-onset neurodegenerative disorder. J Hum Genet 2017;62:525-529.
- Coskran TM, Morton D, Menniti FS, et al. Immunohistochemical localization of phosphodiesterase 10A in multiple mammalian species. J Histochem Cytochem 2006;54:1205-1213.
- Soderling SH, Beavo JA. Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions. Curr Opin Cell Biol 2000;12:174-179.

Supporting Data

Additional Supporting Information may be found in the online version of this article at the publisher's website

Coordinated Reset Vibrotactile Stimulation Shows Prolonged Improvement in Parkinson's Disease

Coordinated reset stimulation delivers brief high-frequency trains in a patterned sequence and may reset the phases of

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

*Correspondence to: Dr. Helen Bronte-Stewart, MD, MSE, Stanford University Department of Neurosurgery, 300 Pasteur Drive, Stanford, CA, 94305; hbs@stanford.edu

Peter A. Tass and Helen Bronte-Stewart are co-senior authors.

Relevant conflicts/financial disclosures: None.

Funding agencies: Funding for this study was provided by the Michael J. Fox Foundation, John A. Blume Foundation, Pelham Olive donation (to P.T.), Robert and Ruth Halperin Foundation, John E. Cahill Family Foundation, and Helen M. Cahill Award for Research in Parkinson's Disease.

Received: 14 June 2017; Revised: 28 August 2017; Accepted: 28 September 2017

© 2017 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.

Published online 18 November 2017 in Wiley Online Library (wileyonlinelibrary.com). DOI: 10.1002/mds.27223

neuronal subpopulations toward a desynchronized state.¹⁻³ Studies have shown that peripheral vibrotactile stimulation accesses central sensory networks and produces a characteristic cortical response.⁴ In this study, we investigated the tolerability and efficacy of peripheral vibrotactile coordinated reset stimulation (PVCRS)⁵ in 5 subjects with idiopathic Parkinson's disease (PD).

Four subjects were off therapy (see Supporting Information); 1 subject was on medication during stimulation. The PVCRS pattern was delivered with C-2 tactors (Engineering Acoustics Inc.; Supporting Information) to both hands, on all fingers (not the thumb), Figure S1A, and consisted of 3 cycles, each containing a randomized sequence of 4 vibratory bursts equally spaced in time and followed by 2 silent cycles off stimulation ("pause"; Fig. S1B).⁵

The evaluation schedule included off-therapy testing before stimulation (baseline, day 1), on-stimulation testing (days 1-3), and off-therapy testing (day 3 and 1 and 4 weeks poststimulation; Fig. S1C). Outcomes included a blinded rating of the Unified Parkinson's Disease Rating Scale (motor, UPDRS III), quantitative measures of forward walking using 9-axis inertial measurement units (APDM Inc.), and the kinematics of repetitive wrist flexion extension (rWFE) using solid-state gyroscopes (Motus Bioengineering). The acute effect of PVCRS compared outcomes at baseline, off therapy, with those on stimulation, whereas cumulative outcomes compared baseline measures with those off therapy, on day 3, and 1 and 4 weeks after PVCRS.

This study demonstrated that 3 days of PVCRS was safe, tolerable, and resulted in acute and cumulative improvements in quantitative measures of gait impairment and bradykinesia in PD. Gait asymmetry, arrhythmicity, and rWFE frequency improved acutely on stimulation on the second day of stimulation (P < 0.001, P < 0.001, and P = 0.006,respectively) and third day of stimulation (P < 0.001,P < 0.001, and P = 0.016, respectively) compared with baseline (Fig. 1A-C). There was a cumulative effect of PVCRS on both gait impairment and wrist bradykinesia (Fig 1D-F). Off therapy, gait asymmetry, wrist rhythm (rWFE CV_{ISI}), and angular velocity (rWFE Vrms) were still better than at baseline, 1 week after PVCRS (P = 0.001, P < 0.05, and P =0.004, respectively) and 4 weeks after PVCRS (P < 0.001, P < 0.05, and P = 0.006, respectively). One subject, who was on medication during stimulation, also demonstrated long-term improvement in gait asymmetry and arrhythmicity. No significant effect was found on the blinded UPDRS III scores across the group.

To our knowledge this is the first demonstration that PVCRS is tolerable and efficacious in PD. There was acute (on stimulation) and cumulative (off therapy) improvement in gait and bradykinesia in PD. The cumulative benefit suggests that peripheral CR stimulation may have a persistent desynchronizing effect on sensorimotor networks, as demonstrated using subthalamic electrical CR neurostimulation.⁶

The improvement in 1 subject, stimulated on medication, suggests that a future PVCRS trial may be possible on medication (Table S2). A sham stimulation condition will be important in future trials to minimize the placebo effect, although this was less likely to have contributed to the cumulative improvement.



FIG. 1. (A-C) Acute and (D-F) long-term effects of peripheral vibrotactile coordinated reset stimulation on gait impairment and wrist bradykinesia. (A) Gait asymmetry and, (B) arrhythmicity decreased significantly from baseline to day 2 and 3 ON stimulation representing more regular gait, while (C) rWFE frequency increased significantly demonstrating diminished wrist bradykinesia. (D) Gait asymmetry decreased significantly while (E) rWFE Vrms and, (F) rWFE CVISI increased significantly from baseline after one week and four weeks indicating the long-term potency of PVCR. Error bars are standard error of the mean.

Acknowledgments: We thank Anca Velisar, Thomas Prieto, Megan Trager, Zack Blumenfeld, Furqan Afzal, and Amaris Martinez for support during experiments and helpful comments.

Judy Syrkin-Nikolau, BA,¹ Raumin Neuville, BS,¹ Johanna O'Day, MS,¹ Chioma Anidi, BA,¹ Mandy Miller Koop, PhD,¹ Talora Martin, BA,¹ Peter A. Tass, MD, PhD,^{2*} Helen Bronte-Stewart, MD, MSE^{1,2*} ¹Stanford University Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California, USA ²Stanford University Department of Neurosurgery, Stanford, California, USA

References

1. Ebert M, Hauptmann C, Tass PA. Coordinated reset stimulation in a large-scale model of the STN-GPe circuit. Front Comput Neurosci 2014;8:154.

- Tass PA. A model of desynchronizing deep brain stimulation with a demand-controlled coordinated reset of neural subpopulations. Biol Cybern 2013;89:81-88.
- Zeitler M, Tass PA. Augmented brain function by coordinated reset stimulation with slowly varying sequences. Front Syst Neurosci 2015;9:49.
- 4. Caetano G, Jousmäki V. Evidence of vibrotactile input to human auditory cortex. NeuroImage 2006;29:15-28.
- Tass PA. Vibrotactile Coordinated Reset Stimulation for the Treatment of Neurological Diseases: Concepts and Device Specifications. Cureus 2017; 9(8): e1535
- Adamchic I. Hauptmann C. Barnikol U, et al. Coordinated reset neuromodulation for Parkinson's disease: proof-of-concept study. Mov Disord Off J Mov Disord Soc 2014;29:1679-1684.

Supporting Data

Additional Supporting Information may be found in the online version of this article at the publisher's website